CN104383612A - 血管支架及其制备方法 - Google Patents

血管支架及其制备方法 Download PDF

Info

Publication number
CN104383612A
CN104383612A CN201410610806.2A CN201410610806A CN104383612A CN 104383612 A CN104383612 A CN 104383612A CN 201410610806 A CN201410610806 A CN 201410610806A CN 104383612 A CN104383612 A CN 104383612A
Authority
CN
China
Prior art keywords
rapamycin
layer
drug
coated
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410610806.2A
Other languages
English (en)
Inventor
胡堃
余均武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huarui (Fujian) Biological Technology Co., Ltd.
Original Assignee
胡堃
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 胡堃 filed Critical 胡堃
Priority to CN201610970699.3A priority Critical patent/CN106581785A/zh
Priority to CN201410610806.2A priority patent/CN104383612A/zh
Publication of CN104383612A publication Critical patent/CN104383612A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06Use of macromolecular materials
    • A61L33/08Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23Carbohydrates
    • A61L2300/232Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

本发明公开一种血管支架,其特征在于,金属支架(4)外侧依次涂覆有固着层(3)、雷帕霉素和聚偏氟乙烯载药层(2)。本发明还涉及制备前述血管支架的方法。本发明提供的血管支架,通过雷帕霉素的缓释,有效防止血管再狭窄的发生。

Description

血管支架及其制备方法
技术领域
本发明涉及一种血管支架及其制备方法。
背景技术
我国的脑卒中发病率极高,为120人/10万,居世界第2位。而其中高达33%的脑卒中是由脑血管动脉狭窄引起的,目前症状性脑血管动脉狭窄的治疗大致分为药物治疗、外科治疗和血管内介入治疗,但药物治疗疗效较差、外科手术风险较大,因此介入治疗脑血管动脉狭窄性疾病的应用逐渐增多。而血管内介入治疗分为单纯球囊扩张术和脑血管动脉支架植入术。单纯球囊扩张术易形成急性内膜夹层、动脉破裂、血管弹性回缩及术后狭窄残余率高等并发症,限制了其在介入治疗中的应用。脑血管动脉植入支架可使血流明显改善,因此血管内支架成形术是目前脑血管动脉狭窄最有效的治疗方法。
然而,最近结果表明,由于脑血管动脉平滑肌细胞含量高,如由椎动脉过渡到基底动脉平滑肌细胞含量由60%上升到85%,而平滑肌细胞增生被公认为是造成支架内狭窄的主要因素,故脑血管动脉支架植入后再狭窄率远高于冠脉。临床研究结果也证实了这一问题的严重性,脑血管支架植入6个月后随访32.4%病例出现了支架内再狭窄,一年后卒中复发率为13.9%。并且,在支架植入过程中经常伴随有急性亚急性血栓形成等并发症情况存在。
发明内容
为了有效避免现有技术中存在的,脑血管支架植入后容易发生再狭窄,和容易发生急性亚急性血栓形成等缺陷,本发明提供一种血管支架,可以有效防止脑血管支架植入后再狭窄和急性亚急性血栓形成的发生。
作为本发明的一个方面,涉及一种血管支架,金属支架4外侧依次涂覆有固着层3、雷帕霉素和聚偏氟乙烯载药层2。雷帕霉素和聚偏氟乙烯载药层2表面还可以涂覆有肝素载药层1。肝素载药层的药物含量为0.7-1.0μg/mm。
固着层2可以为聚丙烯酸酯层。聚丙烯酸酯含量为8-10μg/mm。
雷帕霉素与聚偏氟化乙烯的质量比为:1:7-9,其中,雷帕霉素的含量在15-20μg/mm。作为优选,雷帕霉素与聚偏氟化乙烯的质量比为:1:8,其中,雷帕霉素的含量在16μg/mm。
作为本发明的另一个方面,涉及制备上述血管支架的方法,包括如下步骤:
将聚丙烯酸酯涂覆于金属支架外侧;
在聚丙烯酸酯层表面涂覆雷帕霉素与聚偏氟化乙烯的混合物。
还可以包括如下步骤:
在雷帕霉素与聚偏氟化乙烯层表面涂覆肝素层。
雷帕霉素与聚偏氟化乙烯的混合物中,雷帕霉素与聚偏氟化乙烯的质量比为:1:7-9,其中,雷帕霉素的含量在15-20μg/mm,优选为雷帕霉素与聚偏氟化乙烯的质量比为:1:8,其中,雷帕霉素的含量在16μg/mm。
采用上述方案后,本发明至少能够实现如下有益效果:
1、通过雷帕霉素的缓释,有效防止血管再狭窄的发生;
2、通过肝素的使用,有效防止急性亚急性血栓的形成;
3、通过聚丙烯酸酯的使用,将药效成分层稳定的固定于血管支架内壁,在支架扭曲变形过程中,不易脱落。
附图说明
图1为本发明血管支架剖面示意图。
1为肝素载药层; 2为雷帕霉素和聚偏氟乙烯载药层;3为固着层;4为金属支架。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好的理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
实施例1
如图1所示,本实施例提供的血管支架,在金属支架4外侧依次涂覆有固着层3、雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1。
固着层3为聚丙烯酸酯喷涂或浸涂方式涂覆在金属支架4上形成,聚丙烯酸酯含量为8-10μg/mm,将雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1固着于金属支架4上。本发明发现,使用聚丙烯酸酯涂覆得到的固着层3,具备优良的结合性能,能与金属支架4牢固结合在一起,并在支架系统后续加工工艺及实施介入治疗手术支架在迂曲纤细的血管内运行过程中所述药物复合涂层不发生开裂、脱落等现象。
雷帕霉素与聚偏氟化乙烯的质量比为:1:7,其中,雷帕霉素的含量在18μg/mm。肝素涂层的药物含量在0.7μg/mm。雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1,以喷涂或浸涂方式依次涂覆在固着层3上。本发明中的药物层具备良好的生物相容性。
本实施例所提供雷帕霉素与聚偏氟化乙烯层的药物含量在合理范围内,既具备抑制细胞增殖的功效,又不损害正常细胞。雷帕霉素能在植入150天内按规律稳定释放,有效防止再狭窄的发生。
本实施例中,肝素药物涂层在植入1个月内按规律释放70%,在50天内全部释放完毕,能有效抑制急性亚急性血栓形成。
实施例2
如图1所示,本实施例提供的血管支架,在金属支架4外侧依次涂覆有固着层3、雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1。
固着层3为聚丙烯酸酯喷涂或浸涂方式涂覆在金属支架4上形成,聚丙烯酸酯含量为8-10μg/mm,将雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1固着于金属支架4上。本发明发现,使用聚丙烯酸酯涂覆得到的固着层3,具备优良的结合性能,能与金属支架4牢固结合在一起,并在支架系统后续加工工艺及实施介入治疗手术支架在迂曲纤细的血管内运行过程中所述药物复合涂层不发生开裂、脱落等现象。
雷帕霉素与聚偏氟化乙烯的质量比为:1:8,其中,雷帕霉素的含量在16μg/mm。肝素涂层的药物含量在0.8μg/mm。雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1,以喷涂或浸涂方式依次涂覆在固着层3上。本发明中的药物层具备良好的生物相容性。
本实施例所提供雷帕霉素与聚偏氟化乙烯层的药物含量在合理范围内,既具备抑制细胞增殖的功效,又不损害正常细胞。雷帕霉素能在植入180天内按规律稳定释放,有效防止再狭窄的发生。
本实施例中,肝素药物涂层在植入1个月内按规律释放70%,在50天内全部释放完毕,能有效抑制急性亚急性血栓形成。
实施例3
如图1所示,本实施例提供的血管支架,在金属支架4外侧依次涂覆有固着层3、雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1。
固着层3为聚丙烯酸酯喷涂或浸涂方式涂覆在金属支架4上形成,聚丙烯酸酯含量为8-10μg/mm,将雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1固着于金属支架4上。本发明发现,使用聚丙烯酸酯涂覆得到的固着层3,具备优良的结合性能,能与金属支架4牢固结合在一起,并在支架系统后续加工工艺及实施介入治疗手术支架在迂曲纤细的血管内运行过程中所述药物复合涂层不发生开裂、脱落等现象。
雷帕霉素与聚偏氟化乙烯的质量比为:1:7,其中,雷帕霉素的含量在15μg/mm。肝素涂层的药物含量在0.7μg/mm。雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1,以喷涂或浸涂方式依次涂覆在固着层3上。本发明中的药物层具备良好的生物相容性。
本实施例所提供雷帕霉素与聚偏氟化乙烯层的药物含量在合理范围内,既具备抑制细胞增殖的功效,又不损害正常细胞。雷帕霉素能在植入160天内按规律稳定释放,有效防止再狭窄的发生。
本实施例中,肝素药物涂层在植入1个月内按规律释放70%,在50天内全部释放完毕,能有效抑制急性亚急性血栓形成。
实施例4
如图1所示,本实施例提供的血管支架,在金属支架4外侧依次涂覆有固着层3、雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1。
固着层3为聚丙烯酸酯喷涂或浸涂方式涂覆在金属支架4上形成,聚丙烯酸酯含量为8-10μg/mm,将雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1固着于金属支架4上。本发明发现,使用聚丙烯酸酯涂覆得到的固着层3,具备优良的结合性能,能与金属支架4牢固结合在一起,并在支架系统后续加工工艺及实施介入治疗手术支架在迂曲纤细的血管内运行过程中所述药物复合涂层不发生开裂、脱落等现象。
雷帕霉素与聚偏氟化乙烯的质量比为:1:9,其中,雷帕霉素的含量在20μg/mm。肝素涂层的药物含量在1.0μg/mm。雷帕霉素和聚偏氟乙烯载药层2和肝素载药层1,以喷涂或浸涂方式依次涂覆在固着层3上。本发明中的药物层具备良好的生物相容性。
本实施例所提供雷帕霉素与聚偏氟化乙烯层的药物含量在合理范围内,既具备抑制细胞增殖的功效,又不损害正常细胞。雷帕霉素能在植入170天内按规律稳定释放,有效防止再狭窄的发生。
本实施例中,肝素药物涂层在植入1个月内按规律释放70%,在50天内全部释放完毕,能有效抑制急性亚急性血栓形成。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。

Claims (10)

1.一种血管支架,其特征在于,金属支架(4)外侧依次涂覆有固着层(3)、雷帕霉素和聚偏氟乙烯载药层(2)。
2.权利要求1所述血管支架,其特征在于,金属支架(4)外侧依次涂覆有固着层(3)、雷帕霉素和聚偏氟乙烯载药层(2)和肝素载药层(1)。
3.权利要求2所述血管支架,其特征在于,肝素载药层的药物含量为0.7-1.0μg/mm。
4.权利要求1所述血管支架,其特征在于,固着层2为聚丙烯酸酯层。
5.权利要求4所述血管支架,其特征在于,聚丙烯酸酯含量为8-10μg/mm。
6.权利要求1所述血管支架,其特征在于,雷帕霉素与聚偏氟化乙烯的质量比为:1:7-9,其中,雷帕霉素的含量在15-20μg/mm。
7.权利要求6所述血管支架,其特征在于,雷帕霉素与聚偏氟化乙烯的质量比为:1:8,其中,雷帕霉素的含量在16μg/mm。
8.制备权利要求1-7任一项所述血管支架的方法,其特征在于,包括如下步骤:
将聚丙烯酸酯涂覆于金属支架外侧;
在聚丙烯酸酯层表面涂覆雷帕霉素与聚偏氟化乙烯的混合物。
9.权利要求8所述方法,其特征在于,还包括如下步骤:
在雷帕霉素与聚偏氟化乙烯层表面涂覆肝素层。
10.权利要求8所述方法,其特征在于,雷帕霉素与聚偏氟化乙烯的混合物中,雷帕霉素与聚偏氟化乙烯的质量比为:1:7-9,其中,雷帕霉素的含量在15-20μg/mm。
CN201410610806.2A 2014-11-04 2014-11-04 血管支架及其制备方法 Pending CN104383612A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610970699.3A CN106581785A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法
CN201410610806.2A CN104383612A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410610806.2A CN104383612A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610970699.3A Division CN106581785A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法

Publications (1)

Publication Number Publication Date
CN104383612A true CN104383612A (zh) 2015-03-04

Family

ID=52601627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610970699.3A Pending CN106581785A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法
CN201410610806.2A Pending CN104383612A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610970699.3A Pending CN106581785A (zh) 2014-11-04 2014-11-04 血管支架及其制备方法

Country Status (1)

Country Link
CN (2) CN106581785A (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105435314A (zh) * 2015-12-14 2016-03-30 李雷 覆膜血管支架的制备方法
CN105559944A (zh) * 2015-12-14 2016-05-11 李雷 覆膜血管支架
CN106264781A (zh) * 2015-06-25 2017-01-04 李雷 覆膜支架的制造方法、系统
CN106562838A (zh) * 2015-10-09 2017-04-19 李道远 一种新型心血管支架
CN107049571A (zh) * 2017-05-12 2017-08-18 微创神通医疗科技(上海)有限公司 一种椎动脉支架及其制作方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110665074A (zh) * 2019-10-25 2020-01-10 福建长庚医疗生物科技有限公司 一种肝素涂层组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN202146455U (zh) * 2011-07-05 2012-02-22 张湘鲁 一种心血管复合药物支架
CN203436435U (zh) * 2013-07-01 2014-02-19 雅伦生物科技(北京)有限公司 一种脑血管药物洗脱支架

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN202146455U (zh) * 2011-07-05 2012-02-22 张湘鲁 一种心血管复合药物支架
CN203436435U (zh) * 2013-07-01 2014-02-19 雅伦生物科技(北京)有限公司 一种脑血管药物洗脱支架

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106264781A (zh) * 2015-06-25 2017-01-04 李雷 覆膜支架的制造方法、系统
CN106562838A (zh) * 2015-10-09 2017-04-19 李道远 一种新型心血管支架
CN105435314A (zh) * 2015-12-14 2016-03-30 李雷 覆膜血管支架的制备方法
CN105559944A (zh) * 2015-12-14 2016-05-11 李雷 覆膜血管支架
CN107049571A (zh) * 2017-05-12 2017-08-18 微创神通医疗科技(上海)有限公司 一种椎动脉支架及其制作方法

Also Published As

Publication number Publication date
CN106581785A (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
CN104383612A (zh) 血管支架及其制备方法
Stefanini et al. State of the art: coronary artery stents-past, present and future
Sousa et al. New frontiers in cardiology: drug-eluting stents: Part I
KR100826574B1 (ko) 다공성 층을 갖는 의료장치 및 이를 제조하는 방법
Sousa et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study
Ma et al. Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies
CN103948975B (zh) 一种靶向药物释放介入类医疗器械及其制备方法
US20090287301A1 (en) Coating for medical implants
JP2012500660A5 (zh)
JP2010518944A5 (zh)
EP2380528A1 (en) Medicament eluting apparatus with micro-hole structure capable of storing and releasing multiple medicines and preparation method
AU2007204550A1 (en) Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
CN102860890B (zh) 一种复合载药血管支架及其制备方法
JP2014531933A (ja) 介入医療機器およびその製造方法
JP2021506467A (ja) 装薬式埋め込み医療デバイスおよびその準備方法
JP2014530058A (ja) 介入医療機器およびその製造方法
Koźlik et al. Drug-Eluting Stents: Technical and Clinical Progress
WO2012081850A3 (ko) 티타늄 산화물 박막코팅을 이용한 유전자 전달 스텐트 및 그 제조방법
EP2055328B1 (de) Stent mit einem Grundkörper aus einem bioinerten metallischen Implantatwerkstoff
CN106310395A (zh) 复合载药支架及其制备方法
KR20050092757A (ko) 생체 유치용 스텐트
CN104107459A (zh) 具有时序响应功能的可降解高分子涂层支架及制造方法
JP6761547B2 (ja) アンレキサノクスの新たな使用
US20130004548A1 (en) Medical devices having pharmacological active agent releasing material
CN204840623U (zh) 一种药物洗脱球囊

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161012

Address after: 350002, 14 floor, technical transfer center, No. 611 Industrial Road, Gulou District, Fujian, Fuzhou

Applicant after: Huarui (Fujian) Biological Technology Co., Ltd.

Address before: 102600 No. 1 Xinghua Street (two paragraph), Beijing, Daxing District

Applicant before: Hu Kun

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150304